- Home
- RNXT vs SRZN Comparison
RNXT vs SRZN Comparison
Compare RNXT & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- SRZN
- Stock Information
- Founded
- RNXT 2012
- SRZN 2015
- Country
- RNXT United States
- SRZN United States
- Employees
- RNXT N/A
- SRZN N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- RNXT Health Care
- SRZN Health Care
- Exchange
- RNXT Nasdaq
- SRZN Nasdaq
- Market Cap
- RNXT 33.8M
- SRZN 38.1M
- IPO Year
- RNXT 2021
- SRZN N/A
- Fundamental
- Price
- RNXT $1.50
- SRZN $12.08
- Analyst Decision
- RNXT Strong Buy
- SRZN Strong Buy
- Analyst Count
- RNXT 2
- SRZN 1
- Target Price
- RNXT $6.50
- SRZN $45.00
- AVG Volume (30 Days)
- RNXT 101.2K
- SRZN 53.7K
- Earning Date
- RNXT 11-13-2024
- SRZN 11-06-2024
- Dividend Yield
- RNXT N/A
- SRZN N/A
- EPS Growth
- RNXT N/A
- SRZN N/A
- EPS
- RNXT N/A
- SRZN N/A
- Revenue
- RNXT N/A
- SRZN $10,000,000.00
- Revenue This Year
- RNXT N/A
- SRZN N/A
- Revenue Next Year
- RNXT N/A
- SRZN N/A
- P/E Ratio
- RNXT N/A
- SRZN N/A
- Revenue Growth
- RNXT N/A
- SRZN N/A
- 52 Week Low
- RNXT $0.77
- SRZN $6.00
- 52 Week High
- RNXT $1.86
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- RNXT 64.78
- SRZN 50.51
- Support Level
- RNXT $1.26
- SRZN $10.20
- Resistance Level
- RNXT $1.60
- SRZN $12.51
- Average True Range (ATR)
- RNXT 0.12
- SRZN 2.03
- MACD
- RNXT 0.01
- SRZN -0.29
- Stochastic Oscillator
- RNXT 72.22
- SRZN 24.91
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).